1. Home
  2. UBX vs NXPL Comparison

UBX vs NXPL Comparison

Compare UBX & NXPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • UBX
  • NXPL
  • Stock Information
  • Founded
  • UBX 2009
  • NXPL 1997
  • Country
  • UBX United States
  • NXPL United States
  • Employees
  • UBX N/A
  • NXPL N/A
  • Industry
  • UBX Biotechnology: Pharmaceutical Preparations
  • NXPL Telecommunications Equipment
  • Sector
  • UBX Health Care
  • NXPL Telecommunications
  • Exchange
  • UBX Nasdaq
  • NXPL Nasdaq
  • Market Cap
  • UBX 16.5M
  • NXPL 19.5M
  • IPO Year
  • UBX 2018
  • NXPL N/A
  • Fundamental
  • Price
  • UBX $1.73
  • NXPL $1.11
  • Analyst Decision
  • UBX Strong Buy
  • NXPL
  • Analyst Count
  • UBX 2
  • NXPL 0
  • Target Price
  • UBX $7.00
  • NXPL N/A
  • AVG Volume (30 Days)
  • UBX 303.9K
  • NXPL 889.1K
  • Earning Date
  • UBX 11-04-2024
  • NXPL 11-14-2024
  • Dividend Yield
  • UBX N/A
  • NXPL N/A
  • EPS Growth
  • UBX N/A
  • NXPL N/A
  • EPS
  • UBX N/A
  • NXPL N/A
  • Revenue
  • UBX N/A
  • NXPL $66,482,000.00
  • Revenue This Year
  • UBX N/A
  • NXPL N/A
  • Revenue Next Year
  • UBX $33.62
  • NXPL N/A
  • P/E Ratio
  • UBX N/A
  • NXPL N/A
  • Revenue Growth
  • UBX N/A
  • NXPL 179.89
  • 52 Week Low
  • UBX $0.94
  • NXPL $0.71
  • 52 Week High
  • UBX $2.02
  • NXPL $2.68
  • Technical
  • Relative Strength Index (RSI)
  • UBX 63.32
  • NXPL 48.71
  • Support Level
  • UBX $1.56
  • NXPL $1.09
  • Resistance Level
  • UBX $1.85
  • NXPL $2.30
  • Average True Range (ATR)
  • UBX 0.22
  • NXPL 0.21
  • MACD
  • UBX 0.05
  • NXPL -0.03
  • Stochastic Oscillator
  • UBX 75.96
  • NXPL 5.56

About UBX Unity Biotechnology Inc.

Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells, and creating senolytic medicines. Its medicines target vulnerabilities unique to senescent cells to clear those cells from the human body while leaving normal cells unaffected. The firm focuses on age-associated diseases such as osteoarthritis, eye diseases, and pulmonary diseases. Its drug candidates include, UBX1325 is being developed for age-related diseases of the eye, including diabetic macular edema, or DME, UBX2089, which is a circulating hormone primarily produced in the kidneys and choroid plexus of the brain, which is being researched for multiple neurology indications, and UBX2050.

About NXPL NextPlat Corp

NextPlat Corp is a global e-commerce and healthcare company. Its e-commerce venues form an effective global network serving thousands of consumers, enterprises, and governments. Its healthcare business is focused on improving the lives of patients with complex chronic diseases through patient and provider engagement and their partnerships with payors, pharmaceutical manufacturers, and distributors, offering a broad range of solutions to address the dispensing, delivery, dosing, and reimbursement of clinically intensive, high-cost drugs. The company operate in two segments: e-Commerce Business and Healthcare Business.

Share on Social Networks: